CA2179627C - Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread - Google Patents
Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread Download PDFInfo
- Publication number
- CA2179627C CA2179627C CA002179627A CA2179627A CA2179627C CA 2179627 C CA2179627 C CA 2179627C CA 002179627 A CA002179627 A CA 002179627A CA 2179627 A CA2179627 A CA 2179627A CA 2179627 C CA2179627 C CA 2179627C
- Authority
- CA
- Canada
- Prior art keywords
- concentration
- amount
- hydroxycarbamide
- dideoxynucleoside
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 title claims abstract description 86
- 229960001330 hydroxycarbamide Drugs 0.000 title claims abstract description 86
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 13
- 239000002777 nucleoside Substances 0.000 title description 5
- 230000001177 retroviral effect Effects 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 43
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 17
- 210000005260 human cell Anatomy 0.000 claims abstract 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 38
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 10
- 238000011282 treatment Methods 0.000 abstract description 18
- 239000011885 synergistic combination Substances 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 12
- 239000002342 ribonucleoside Substances 0.000 abstract 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 35
- 208000031886 HIV Infections Diseases 0.000 description 20
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 20
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 18
- 208000030507 AIDS Diseases 0.000 description 14
- 108010047620 Phytohemagglutinins Proteins 0.000 description 14
- 230000001885 phytohemagglutinin Effects 0.000 description 14
- 229960002555 zidovudine Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 102000000588 Interleukin-2 Human genes 0.000 description 12
- 108010002350 Interleukin-2 Proteins 0.000 description 12
- 230000029812 viral genome replication Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 108020005202 Viral DNA Proteins 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 208000037357 HIV infectious disease Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000007442 viral DNA synthesis Effects 0.000 description 4
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 206010038997 Retroviral infections Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229960002656 didanosine Drugs 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940124522 antiretrovirals Drugs 0.000 description 2
- 239000003903 antiretrovirus agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- OCLZPNCLRLDXJC-NTSWFWBYSA-N 2-amino-9-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](CO)O1 OCLZPNCLRLDXJC-NTSWFWBYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/169,253 US5521161A (en) | 1993-12-20 | 1993-12-20 | Method of treating HIV in humans by administration of ddI and hydroxycarbamide |
| US08/169,253 | 1993-12-20 | ||
| PCT/IB1995/000153 WO1995017899A2 (en) | 1993-12-20 | 1994-12-20 | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2179627A1 CA2179627A1 (en) | 1995-07-06 |
| CA2179627C true CA2179627C (en) | 2000-02-22 |
Family
ID=22614846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002179627A Expired - Fee Related CA2179627C (en) | 1993-12-20 | 1994-12-20 | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5521161A (forum.php) |
| EP (1) | EP0735890B1 (forum.php) |
| AT (1) | ATE216245T1 (forum.php) |
| AU (1) | AU1821295A (forum.php) |
| CA (1) | CA2179627C (forum.php) |
| DE (1) | DE69430440T2 (forum.php) |
| DK (1) | DK0735890T3 (forum.php) |
| ES (1) | ES2173948T3 (forum.php) |
| OA (1) | OA10721A (forum.php) |
| PT (1) | PT735890E (forum.php) |
| TW (1) | TW283645B (forum.php) |
| WO (1) | WO1995017899A2 (forum.php) |
| ZA (1) | ZA949219B (forum.php) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| US6346627B1 (en) * | 1990-02-01 | 2002-02-12 | Emory University | Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers |
| SE9003151D0 (sv) * | 1990-10-02 | 1990-10-02 | Medivir Ab | Nucleoside derivatives |
| EP0610444B1 (en) | 1991-10-31 | 2003-01-29 | ELFORD, Howard L. | Use of a polyhydroxybenzamide or a derivative thereof in the manufacture of a medicament for treating viral infectious diseases |
| ATE273700T1 (de) * | 1993-05-21 | 2004-09-15 | Us Gov Health & Human Serv | Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren |
| US6677310B1 (en) * | 1999-04-21 | 2004-01-13 | Nabi | Ring-expanded nucleosides and nucleotides |
| US5521161A (en) * | 1993-12-20 | 1996-05-28 | Compagnie De Developpment Aguettant S.A. | Method of treating HIV in humans by administration of ddI and hydroxycarbamide |
| US6093702A (en) * | 1993-12-20 | 2000-07-25 | The United States Of America As Represented By The Department Of Health And Human Services | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread |
| CA2195091A1 (en) * | 1994-07-15 | 1996-02-01 | Antonio De Flora | Dinucleoside-5',5'-pyrophosphates |
| US5703058A (en) | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
| US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
| US5869493A (en) | 1996-02-16 | 1999-02-09 | Medivir Ab | Acyclic nucleoside derivatives |
| US6511848B2 (en) * | 1996-04-17 | 2003-01-28 | Winfried Albert | Process for producing and multiplying lymphocytes |
| US5719132A (en) * | 1996-06-27 | 1998-02-17 | Bristol-Myers Squibb Company | Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil |
| US5886165A (en) * | 1996-09-24 | 1999-03-23 | Hybridon, Inc. | Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments |
| US5932570A (en) * | 1996-11-08 | 1999-08-03 | Dupont Pharmaceuticals Company | 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors |
| US6218386B1 (en) | 1996-11-08 | 2001-04-17 | Dupont Pharmaceuticals | A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor |
| US6686462B2 (en) * | 1997-02-28 | 2004-02-03 | The Regents Of The University Of California | Antiviral compounds and methods of administration |
| US6114312A (en) * | 1997-03-07 | 2000-09-05 | Research Institute For Genetic And Human Therapy (R.I.G.H.T.) | Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor |
| JP2001521548A (ja) * | 1997-03-20 | 2001-11-06 | コンパニー デ デベロップマー アーギュタント | 特にレトロウイルス伝播を阻害するための、少なくとも２種の逆転写酵素阻害剤とヒドロキシカルバミドとの混合物 |
| WO1998050347A1 (en) * | 1997-05-05 | 1998-11-12 | The Regents Of The University Of California | Naphthols useful in antiviral methods |
| DE69840216D1 (de) * | 1997-08-08 | 2008-12-24 | Celmed Oncology Usa Inc | Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden |
| US20020022034A1 (en) * | 1997-09-15 | 2002-02-21 | Julianna Lisziewicz | Therapeutic DNA vaccination |
| KR100286373B1 (ko) * | 1997-10-17 | 2001-04-16 | 윤종용 | 적외선 데이터 통신을 위한 휴대용 컴퓨터 |
| ES2172303T3 (es) | 1998-01-23 | 2002-09-16 | Newbiotics Inc | Agentes terapeuticos obtenidos por catalisis enzimatica. |
| US7462605B2 (en) * | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| US6015796A (en) * | 1998-03-11 | 2000-01-18 | Zeria Pharmaceutical Co., Ltd. | Method for treating AIDS |
| US6251874B1 (en) * | 1998-03-26 | 2001-06-26 | Research Institute For Genetic And Human Therapy (R.I.G.H.T.) | Method of inhibiting human immunodeficiency virus using hydroxurea and a reverse transcriptase inhibitor in vivo |
| US6194391B1 (en) * | 1998-06-24 | 2001-02-27 | Emory University | 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol |
| WO2000045844A1 (en) * | 1999-02-03 | 2000-08-10 | Franco Lori | Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv |
| US6020325A (en) * | 1999-03-09 | 2000-02-01 | Zeria Pharmaceutical Co., Ltd. | Method for inhibiting replication of HIV |
| CA2378187C (en) | 1999-07-22 | 2011-09-13 | Newbiotics, Inc. | Methods for treating therapy-resistant tumors |
| US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
| CA2380924C (en) | 1999-08-13 | 2008-02-19 | University Of Maryland Biotechnology Institute | Compositions for treating viral infections, and methods therefor |
| NL1012825C2 (nl) * | 1999-08-13 | 2001-02-23 | Faculteit Geneeskunde Universi | Farmaceuticum voor de behandeling van virale infecties in het bijzonder van het humane immunodeficiency virus (HIV). |
| WO2002056832A2 (en) * | 2001-01-19 | 2002-07-25 | Newbiotics, Inc. | Methods to treat autoimmune and inflammatory conditions |
| WO2003100009A2 (en) * | 2002-05-23 | 2003-12-04 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8324800D0 (en) * | 1983-09-15 | 1983-10-19 | Pasteur Institut | Antigens |
| HU196607B (en) * | 1985-05-15 | 1988-12-28 | Wellcome Found | Process for producing dideoxy-nucleosides and pharmaceutics comprising such compounds |
| AU570853B2 (en) * | 1985-08-26 | 1988-03-24 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases |
| US5110600A (en) * | 1988-01-25 | 1992-05-05 | The Regents Of The University Of California | Method of treating viral infections with amino acid analogs |
| US5026687A (en) * | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
| US5300059A (en) * | 1991-11-19 | 1994-04-05 | Hydro Slip Technologies Inc. | Bloodbag and method of making same |
| ATE273700T1 (de) * | 1993-05-21 | 2004-09-15 | Us Gov Health & Human Serv | Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren |
| US5521161A (en) * | 1993-12-20 | 1996-05-28 | Compagnie De Developpment Aguettant S.A. | Method of treating HIV in humans by administration of ddI and hydroxycarbamide |
-
1993
- 1993-12-20 US US08/169,253 patent/US5521161A/en not_active Expired - Lifetime
-
1994
- 1994-11-21 ZA ZA949219A patent/ZA949219B/xx unknown
- 1994-12-15 TW TW083111742A patent/TW283645B/zh active
- 1994-12-20 DE DE69430440T patent/DE69430440T2/de not_active Expired - Lifetime
- 1994-12-20 AU AU18212/95A patent/AU1821295A/en not_active Abandoned
- 1994-12-20 CA CA002179627A patent/CA2179627C/en not_active Expired - Fee Related
- 1994-12-20 WO PCT/IB1995/000153 patent/WO1995017899A2/en active IP Right Grant
- 1994-12-20 ES ES95909917T patent/ES2173948T3/es not_active Expired - Lifetime
- 1994-12-20 AT AT95909917T patent/ATE216245T1/de not_active IP Right Cessation
- 1994-12-20 EP EP95909917A patent/EP0735890B1/en not_active Expired - Lifetime
- 1994-12-20 DK DK95909917T patent/DK0735890T3/da active
- 1994-12-20 PT PT95909917T patent/PT735890E/pt unknown
-
1996
- 1996-03-18 US US08/617,421 patent/US5736527A/en not_active Expired - Lifetime
- 1996-06-20 OA OA60849A patent/OA10721A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2179627A1 (en) | 1995-07-06 |
| OA10721A (en) | 2002-12-09 |
| WO1995017899A2 (en) | 1995-07-06 |
| EP0735890B1 (en) | 2002-04-17 |
| DE69430440D1 (de) | 2002-05-23 |
| EP0735890A1 (en) | 1996-10-09 |
| AU1821295A (en) | 1995-07-17 |
| TW283645B (forum.php) | 1996-08-21 |
| PT735890E (pt) | 2002-09-30 |
| US5521161A (en) | 1996-05-28 |
| ATE216245T1 (de) | 2002-05-15 |
| US5736527A (en) | 1998-04-07 |
| DK0735890T3 (da) | 2002-08-05 |
| ZA949219B (en) | 1995-08-01 |
| DE69430440T2 (de) | 2002-11-14 |
| ES2173948T3 (es) | 2002-11-01 |
| WO1995017899A3 (en) | 1995-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2179627C (en) | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread | |
| US6093702A (en) | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread | |
| Harakeh et al. | Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells. | |
| JP2001500471A (ja) | プロテアーゼインヒビターの生物学的及び抗ウイルス活性を改善する方法 | |
| JPH0125A (ja) | ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物 | |
| TURANO et al. | Inhibitory effect of papaverine on HIV replication in vitro | |
| EP0255420B1 (en) | Antiviral agent for inhibiting growth of virus of acquired immune deficiency syndrome (aids) | |
| CA2227688C (en) | Methods and compositions for inhibition of viral replication | |
| JPS62215535A (ja) | ウイルス感染の予防および治療用組成物 | |
| AU718325B2 (en) | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread | |
| FR2694693B1 (fr) | Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH. | |
| CN109864990A (zh) | 巴利卡替在制备抗丝状病毒感染药物中的应用 | |
| CN111265502B (zh) | 香紫苏醇和香紫苏内酯在抗丝状病毒感染中的应用 | |
| Pätzold et al. | Novel indolocarbazole protein kinase C inhibitors prevent reactivation of HIV-1 in latently infected cells | |
| CN105362284B (zh) | 阿奇霉素和泰利霉素在抗埃博拉病毒感染中的应用 | |
| WO1995017875A2 (en) | MIXTURES OF DIDEOXYNUCLEOSIDES AND D-ASPARTIC ACID β-HYDROXAMATE FOR INHIBITING RETROVIRAL SPREAD | |
| AU743942B2 (en) | Mixtures of at least two reverse transcriptase inhibitors and hydroxycarbamide, in particular for inhibiting retroviral spread | |
| WO1994004160A1 (en) | Treatment of human viral infections | |
| JPH03227925A (ja) | エイズ原因ウィルスに対する抗ウイルス剤 | |
| JPH0551565B2 (forum.php) | ||
| JP2990015B2 (ja) | 抗ｈｉｖ剤 | |
| CN115844926A (zh) | 去乙酰化酶抑制剂与nk细胞在制备激活并清除潜伏性hiv病毒药物方面的应用 | |
| JPH0551566B2 (forum.php) | ||
| Vecchiet et al. | ADVANCEMENTS IN HIV TREATMENT AND PREVENTION: FOCUSING ON CABOTEGRAVIR AND LENACAPAVIR | |
| JPH01163122A (ja) | 抗レトロウイルス剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |